Even With Insurance, the COVID Drug Remdesivir Is Shockingly Expensive

Even With Insurance, the COVID Drug Remdesivir Is Shockingly Expensive
Gilead Sciences, the pharmaceutical company behind the COVID-19 treatment remdesivir , just announced what it will charge for the antiviral drug.

Patients with health insurance from a private company can expect to pay about $520 for a single dose, The Wall Street Journal reports . That comes out to $3,120 for the five-day treatment the vast majority of patients receive, and $5,720 for a ten-day course. Because remdesivir may be the first COVID-19 treatment to receive full FDA approval, its price tag could set the precedent for other new treatments that emerge down the road, though the WSJ reports that the potential approval of the vastly-cheaper dexamethasone could drive down the cost of remdesivir instead.

The high cost — which will be reduced to $390 per dose under government insurance like Medicare — will be enacted in July and is motivated by Gilead trying to recoup its research and development investments as it ships the drug out to hospitals around the world. And besides, Gilead CEO Daniel O’Day told the WSJ, patients may still end up paying a lower hospital bill than they would have without remdesivir if the drug shortens their stay.

Other countries are likely to negotiate prices similar to the Medicare costs when they buy from Gilead, according to the WSJ. But in countries like Bangladesh, where Gilead has licensed the medication to generic drugmakers, the cost for a full treatment course could be under $1,000 — because the raw materials for a full treatment course of remdesivir cost less than $10 .

Remdesivir was first approved under an FDA emergency authorization back in May. At the time, data suggested it could cut a coronavirus patient’s hospital stay by an average of four days compared to those receiving standard treatments without remdesivir. Given the cost per night of staying in a hospital’s COVID-19 ward, heading home sooner means a significantly lower bill.
News Topics :
Similar Articles :
Reuters Gilead Sciences Inc GILD.O faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected...
Reuters Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID 19 given a five day course of the treatment, while...
Reuters A top U.S. health official said Gilead Sciences Inc’s experimental antiviral drug remdesivir is likely to become the standard of care for COVID 19 after early results from a...
Top Stories
Researchers released some good news about a possible treatment for coronavirus Wednesday evidence that the experimental drug remdesivir might help patients recover more quickly from the infection. The U.S....
WASHINGTON Reuters Gilead Science Inc’s GILD.O antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID 19 on Friday, clearing the...